Related Experiment Video

Updated: Jun 18, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Calcitriol inhibits Ether-à go-go potassium channel expression and cell proliferation in human breast cancer cells

Rocío García-Becerra1, Lorenza Díaz, Javier Camacho

  • 1Department of Reproductive Biology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No 15, Tlalpan 14000 México, DF, Mexico.

Experimental Cell Research
|November 26, 2009
PubMed

Insights

Calcitriol, a vitamin D hormone, suppresses breast cancer cell proliferation by reducing Ether-à-go-go (Eag1) potassium channel expression via the vitamin D receptor (VDR). This reveals a new therapeutic target for breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Calcitriol exhibits antiproliferative effects in various cell types, but its mechanism in breast carcinoma is not fully understood.
  • Ether-à-go-go (Eag1) potassium channels are linked to oncogenesis and breast cancer cell proliferation.
  • Both calcitriol and Eag1 influence cell cycle progression, suggesting a potential regulatory relationship.

Purpose of the Study:

  • To investigate the regulatory effect of calcitriol on Eag1 expression in human breast tumor cells.
  • To uncover novel molecular mechanisms underlying calcitriol's antiproliferative activity in breast cancer.
  • To explore the role of the vitamin D receptor (VDR) in this process.

Main Methods:

  • Reverse transcription real-time PCR (RT-qPCR) to quantify Eag1 mRNA levels.
  • Immunocytochemistry and Western blot to assess protein expression and localization of Eag1 and VDR.
  • Cell proliferation assays, including potentiation with astemizole (Eag1 inhibitor).

Main Results:

  • Calcitriol significantly suppressed Eag1 expression in a VDR-dependent manner.
  • Inhibition of Eag1 expression correlated with reduced breast cancer cell proliferation.
  • Eag1 and VDR levels were elevated in invasive-ductal carcinoma compared to fibroadenoma.

Conclusions:

  • Calcitriol exerts antiproliferative effects in breast cancer by downregulating Eag1 expression through VDR.
  • This study identifies a novel mechanism for calcitriol's action and highlights VDR as a potential therapeutic target.
  • Targeting VDR may offer new strategies for breast cancer treatment and prevention.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Synthesis and Functions of Calcitonin00:51

Synthesis and Functions of Calcitonin

Calcitonin, a vital polypeptide hormone, regulates calcium levels within body fluids. It is released by the parafollicular cells, also known as C cells, situated in the follicular epithelium of the thyroid gland. Calcitonin responds to fluctuations in blood calcium levels and the influence of gastrointestinal hormones like gastrin and cholecystokinin.
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...